Adicet Bio Q2 net loss $21.4M; prula-cel Phase 1 update expected 3Q2026 with 22 LN/SLE patients

Adicet Bio, Inc.

Q2 2026 net loss $21.4M ($1.99/share); cash $118.2M sufficient into 2H2027.
Phase 1 prula-cel update in 3Q2026: 22 LN/SLE patients with ≥6 months follow-up, 13 with ≥12 months.
FDA alignment on potential pivotal trial design for LN; start-up activities planned 2H2026.
Regulatory filing for ADI-212 in mCRPC expected 3Q2026; Phase 1 enrollment anticipated 4Q2026.
Lloyd Klickstein appointed Interim CMO following departure of Dr. Julie Maltzman.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.